Paliperidone palmitate injection for the acute and maintenance treatment of schizophrenia in adults.
Paliperidone palmitate injection for the acute and maintenance treatment of schizophrenia in adults.
复制标题
棕榈酮棕榈酸棕榈酸酯注射，用于成人精神分裂症的急性和维持治疗。
DOI：
10.2147/ppa.s20657
复制
发表时间：
2012
影响因子：
2.2
通讯作者：
Bishop JR
中科院分区：
文献类型：
--
作者：
Kim S;Solari H;Weiden PJ;Bishop JR
目的：回顾帕利培酮棕榈酸酯在精神分裂症患者治疗中的应用。本文对已发表的帕利哌酮棕榈酸酯治疗精神分裂症的临床试验数据进行了评价。四项短期、随机、双盲、安慰剂对照试验研究了帕利培酮棕榈酸酯治疗精神分裂症急性发作的疗效。帕利培酮棕榈酸酯也被研究作为一种维持治疗，以防止或延缓缓解期精神分裂症的复发。此外，在三项研究中，帕利培酮棕榈酸酯与利培酮长效注射剂的非劣效性进行了比较。在四项急性治疗研究中，通过阳性和阴性症状量表总分衡量，帕利培酮棕榈酸酯已被证明在减轻症状方面有效。在维持治疗研究中，帕利培酮棕榈酸酯被发现在预防或推迟缓解期精神分裂症患者首次复发时间方面比安慰剂更有效。此外，在两项研究中，帕利培酮棕榈酸酯被证明不逊于利培酮长效注射剂。在所有临床试验中都显示出相当好的耐受性。急性治疗阶段应该开始，第一天234毫克，第八天156毫克，然后根据临床研究的疗效和耐受性结果，推荐每月39-234毫克的维持量。提供最佳的长期治疗可能是具有挑战性的。帕利培酮棕榈酸酯即使在门诊也可以作为一种急诊治疗，而且患者对它的耐受性很好。此外，它在启动时不需要重叠的口服抗精神病药物补充，每月服用一次。
To review the use of paliperidone palmitate in treatment of patients with schizophrenia. Published clinical trial data for the development and utilization of paliperidone palmitate for the treatment of schizophrenia were assessed in this review. Four short-term, randomized, double-blind, placebo-controlled trials investigated the efficacy of paliperidone palmitate in acute exacerbation of schizophrenia. Paliperidone palmitate was also studied as a maintenance treatment to prevent or delay relapse in stable schizophrenia. In addition, paliperidone palmitate was compared to risperidone long-acting injection for noninferiority in three studies. Paliperidone palmitate has been shown to be effective in reducing symptoms as measured by the Positive and Negative Syndrome Scale total scores in the four acute treatment studies. In the maintenance treatment studies, paliperidone palmitate was found to be more effective than placebo in preventing or delaying the time to first relapse in stable schizophrenia patients. In addition, paliperidone palmitate was shown to be noninferior to risperidone long-acting injection in two studies. It was shown to be reasonably well tolerated in all clinical trials. Acute treatment phase should be initiated with a dose of 234 mg on day one and 156 mg on day eight, followed by a recommended monthly maintenance dose of 39–234 mg based on efficacy and tolerability results from the clinical studies. Providing an optimal long-term treatment can be challenging. Paliperidone palmitate can be used as an acute treatment even in outpatient setting, and it has shown to be well tolerated by patients. Also, it does not require overlapping oral antipsychotic supplementation while being initiated, and is dosed once per month.